Therefore, MOG IgG should be actively screened for ON Sclerosis besides intracranial lesions, these patients also sufferįrom ON. Patients with acute disseminated encephalomyelitis and multiple MOG IgG is also detected in the serum of certain adolescent Indicated that MOG IgG caused myelin changes and altered theĮxpression of axonal proteins within two weeks, but did not produceĪny inflammation, axonal loss or neuronal or astrocyte death, whileĪQP4 IgG produced complement-mediated myelin loss, and neuronal andĪstrocyte death with limited recovery at two weeks. The results with those obtained by AQP4 IgG injection. IgG, sourced from patients with NMO, into mouse brains and compared Pathogenesis in these serum AQP4 IgG (−) NMO-ON patients. Is therefore speculated that MOG IgG is involved in the Oligodendrocyte glycoprotein (MOG) IgG (+) ( 4, 5), and it It has been reported that AQP4 IgG (−) NMO-ON patients are myelin ![]() Potential alternative biomarkers for AQP4 IgG (−) NMO-ON patients. NMO-ON were proposed, and it was suggested to actively search for The International NMO Diagnostic Group in 2015 ( 3) diagnostic criteria for serum-negative New diagnostic criteria for NMO-ON were developed by Patients have an AQP4 IgG (−) status ( 2). However, a clinical study indicated that 10–20% of NMO-ON Is helpful for the early diagnosis and prognostication of NMO-ON Detection of AQP4 IgG, as a clinicalīiomarker for identifying NMO-ON and other demyelinating diseases, (−) patients, and the rate of progression to NMO-ON is faster inĪQP4 IgG (+) patients. The probability of progressing to NMO-ON inĪQP4 IgG (+) patients is significantly higher than that of AQP4 IgG (AQP4) immunoglobulin G (IgG) (+) status has a decisive role in theĭiagnosis of NMO-ON. Has a higher disability rate compared with IDON, and an aquaporin-4 (NMO-ON) and ON associated with other central nervous system Neuritis (MS-ON), neuromyelitis optica-associated optic neuritis Neuritis (IDON), also known as multiple sclerosis-associated optic Which is further subdivided into idiopathic demyelinating optic Optic nerve disease that occurs most frequently in young and Inflammatory lesions involving the optic nerve it is a blinding Optic neuritis (ON) refers to a spectrum of Furthermore, MOG antibody is present in the serum of patients with neuromyelitis optica spectrum disorders and may be a potential biomarker for these conditions. MOG antibody may be detected in the serum of certain RON patients, which have unique and different characteristics from AQP4 antibody‑positive RON patients, so it may be used as a prognostic biomarker for RON. The visual acuity at onset of MOG‑RON was not inferior to that of AQP4‑RON, and the visual recovery degree of MOG‑RON was better (P<0.05). ![]() Compared with the AQP4‑RON patients, there were relatively less MOG‑RON patients (63.6 vs. 95.0%) and the canal segment and intracranial segment of the optic canal were less involved (P<0.05). Of the 43 RON patients, 2.33% was both MOG and AQP4 antibody‑positive, 27.91% were MOG antibody‑positive. ![]() The characteristics of MOG antibody‑positive RON were summarized. The differences in the demographics, clinical features, characteristics of imaging examination, vision at onset and visual function recovery at 6 months after treatment were compared among the different groups. Clinical data were collected and all patients were followed up for 6 months, with parameters observed including the visual acuity, visual field and ocular fundus. According to the results, the 43 patients were divided into four groups, namely the MOG antibody‑positive group (n=11), the AQP4 antibody‑positive group (n=20), the MOG/AQP4 antibody‑positive group (n=1) and the MOG/AQP4 antibody‑negative group (n=11). The serum was collected from all patients, and the MOG and AQP4 antibodies were detected via the CBA. A total of 43 RON patients admitted to Beijing Tongren Hospital from December 2014 to May 2015 were enrolled, including 11 males and 32 females. Furthermore, the clinical features of MOG antibody‑positive recurrent optic neuritis (MOG‑RON) were assessed. The present study aimed to detect myelin oligodendrocyte glycoprotein (MOG) and aquaporin‑4 (AQP4) antibodies in serum specimens of patients with recurrent optic neuritis (RON) through establishing 293 cells with stable expression of MOG and the complete genomic sequence as the substrate using a cell‑based assay (CBA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |